• Revathy Manickavasagar and Raj Thuraisingham.
• Royal London Hospital, London, UK raj.thuraisingham@nhs.net.
• Clin Med (Lond). 2020 Mar 1; 20 (2): 142145142-145.

AbstractIt is well recognised that kidney transplant recipients have an increased risk of cancers compared with the age and gender matched general population. Malignancy is one of the commonest causes of death among this cohort after cardiovascular disease. This increased risk is largely attributable to the effect of immunosuppression, which impairs T cell function, immunosurveillance and the immunological control of oncogenic viral infections. Cancer related mortality rates are also higher in solid organ transplant recipients compared with the general population. While early diagnosis may improve outcomes in these patients, cancer screening is debatable given the lack of randomised controlled trials in this cohort, and treatment is often challenging. This article reviews the epidemiology and risk factors for the development of malignancy in the post-transplant setting, as well as screening guidelines for specific malignancies of which patients are at particular risk.© Royal College of Physicians 2020. All rights reserved.

14 keywords...

hide…